Enliven Therapeutics, Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. The filing was signed March 14, 2024. Enliven is a clinical-stage oncology biopharmaceutical company with no approved products and no product revenue.
Business context and pipeline
- ELVN-001: A selective BCR-ABL inhibitor in a Phase 1 trial for chronic myeloid leukemia (CML). The company planned to present preliminary Phase 1a safety and efficacy data in Q2 2024 and expected to initiate Phase 1b dose escalation by mid-2024.
- ELVN-002: A selective, CNS-penetrant HER2 inhibitor in Phase 1 dose escalation for HER2-altered solid tumors. Enliven planned to share initial data in 2024. The FDA cleared an additional combination-trial IND in Q1 2024; enrollment was expected by mid-2024.
- The company had nominated a third development candidate and completed its IND-enabling studies, but said it would prioritize its two lead programs before potentially starting another clinical trial.
- Enliven completed its merger with Imara Inc. on February 23, 2023, accounted for as a reverse recapitalization. Former Enliven stockholders owned approximately 84% of the combined company immediately after the merger; the company also completed a $164.5 million pre-merger financing.
Financial results and position
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $64.6 million | $31.0 million |
| General and administrative expense | $19.0 million | $7.8 million |
| Total operating expenses / operating loss | $83.5 million | $38.8 million |
| Interest income and other, net | $11.9 million | $1.1 million |
| Net loss | $71.6 million | $37.7 million |
| Basic and diluted loss per share | $2.01 | $12.05 |
| Net cash used in operating activities | $61.3 million | $32.1 million |
Operating expenses rose $44.7 million year over year. R&D expense increased $33.6 million, principally from clinical-trial and manufacturing costs and higher employee-related costs. G&A expense increased $11.2 million, including higher stock-based compensation and professional services. Interest income rose with higher investment balances and rates. Margins are not meaningful because the company had no revenue.
- Liquidity: At year-end, cash and cash equivalents were $100.1 million and marketable securities were $153.0 million, or $253.1 million combined. Management expected these resources to fund planned operations and capital needs for at least 12 months from the filing date; elsewhere, the filing said the cash position was expected to fund operations into early 2026.
- Cash flows: Investing activities used $148.4 million, mainly reflecting purchases of marketable securities, partly offset by maturities. Financing activities provided $234.3 million, including net financing proceeds and cash acquired in the reverse recapitalization.
- Balance sheet: Total assets were $271.9 million, total liabilities $26.0 million, and stockholders’ equity $245.9 million. The company reported no debt outstanding. The $10.0 million contingent value right asset was matched by a $10.0 million liability and therefore did not represent net liquidity.
- Other: Accumulated deficit was $154.4 million. Enliven had no off-balance-sheet arrangements. Operating lease obligations due in 2024 were $341,000.
Outlook, risks and unusual items
- Enliven expects continued operating losses and negative operating cash flows, with expenses increasing as it advances ELVN-001, ELVN-002 and combination studies. It has not provided specific financial guidance or a profitability timeline.
- The company expects to need substantial additional capital before completing development. A $400 million shelf registration was effective, and an at-the-market program could sell up to $200 million of stock; no shares had been sold under that program by December 31, 2023. Future financing could dilute shareholders or impose restrictive terms.
- Key risks include early-stage clinical uncertainty, safety or efficacy failures, trial enrollment and execution delays, competition, dependence on third-party manufacturers and CROs, supply disruption, intellectual-property challenges, and regulatory, reimbursement and financing uncertainty.
- In March 2024, Enliven received notice that a $10 million milestone tied to assets sold before the merger had been achieved, with payment expected within 30 days of achievement. The corresponding CVR proceeds are payable to eligible former Imara stockholders, net of qualifying expenses; this was a subsequent event, not year-end cash.
- The company reported no material litigation and no cybersecurity incident determined to be material. Management concluded disclosure controls and internal control over financial reporting were effective at year-end; the auditor was not engaged to attest to internal-control effectiveness.
Important facts for investors to verify
- Whether planned 2024 ELVN-001 and ELVN-002 clinical data releases occurred, and what the complete safety, efficacy and dose-selection results showed.
- Actual cash burn and runway against the stated funding estimates, including the impact of clinical-trial expansion and any additional financing.
- Whether the March 2024 milestone payment was received and how CVR distributions and qualifying expenses were handled.
- Clinical-trial enrollment, timelines, manufacturing supply and competitive developments for both lead programs.
- Potential dilution from outstanding options and future equity issuance; 5.8 million stock options were outstanding at December 31, 2023.